Phase 1 Safety and Pharmacokinetic Study of AI-700 in Patients With Diminished DLCO and COPD and/or CHF

Completed · Phase 1

Conditions studied: Congestive Heart Failure, Chronic Obstructive Pulmonary Disease

In brief

This study was conducted to evaluate the safety and pharmacokinetics of an echocardiographic contrast agent, AI-700, in patients with moderate to severe chronic obstructive pulmonary disease (COPD) and/or congestive heart failure (CHF).

Key facts

Study ID

NCT00156780

Run by

Acusphere

Starts

2004-08-01

Expected to finish

2005-07-01

Last updated by the study team

2006-10-23

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Acusphere, Inc. — Watertown, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.